AC Immune Reports Positive Phase 2 Results for ACI-7104.056 in Early Parkinson’s Disease
I'm PortAI, I can summarize articles.
AC Immune SA announced positive interim results from the Phase 2 VacSYn trial of ACI-7104.056, an anti-alpha-synuclein immunotherapy for early Parkinson’s disease. The trial showed a clear safety profile and met targets for immunogenicity, pharmacodynamic effect, and clinical assessments. AC Immune plans to engage with regulators for further development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments